2022
CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES: TREATMENT SATISFACTION, QUALITY OF LIFE AND DIABETES RELATED SYMPTOMS WHEN RECEIVING SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR VERSUS OTHER NONINULIN DIABETES MEDICATIONS
Ding Q, Spatz E, Isaacs D, Bena J, Morrison S, Levay M, West L, Combs P, Albert N. CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES: TREATMENT SATISFACTION, QUALITY OF LIFE AND DIABETES RELATED SYMPTOMS WHEN RECEIVING SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR VERSUS OTHER NONINULIN DIABETES MEDICATIONS. Journal Of The American College Of Cardiology 2022, 79: 1547. DOI: 10.1016/s0735-1097(22)02538-4.Peer-Reviewed Original Research
2021
2020 ACC/AHA guideline for the management of patients with valvular heart disease A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Members W, Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM, Thompson A, Toly C, Members A, O'Gara PT, Beckman JA, Levine GN, Al-Khatib SM, Armbruster A, Birtcher KK, Ciggaroa J, Deswal A, Dixon DL, Fleisher LA, de las Fuentes L, Goldberger Z, Gorenek B, Haynes N, Hernandez A, Hlatky M, Joglar J, Jones W, Marine J, Mark D, Palaniappan L, Piano M, Spatz E, Tamis-Holland J, Wijeysundera D, Woo Y. 2020 ACC/AHA guideline for the management of patients with valvular heart disease A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal Of Thoracic And Cardiovascular Surgery 2021, 162: e183-e353. PMID: 33972115, DOI: 10.1016/j.jtcvs.2021.04.002.Peer-Reviewed Original Research
2018
Is diabetes mellitus equivalent to atherosclerotic cardiovascular disease from a healthcare cost perspective? Insights from the Medical Expenditure Panel Survey
Feldman DI, Valero-Elizondo J, Salami JA, Rana JS, Ogunmoroti O, Okunrintemi V, Osondu CU, Spatz ES, Virani SS, Blankstein R, Blaha MJ, Veledar E, Nasir K. Is diabetes mellitus equivalent to atherosclerotic cardiovascular disease from a healthcare cost perspective? Insights from the Medical Expenditure Panel Survey. Cardiovascular Endocrinology & Metabolism 2018, 7: 64-67. PMID: 31646284, PMCID: PMC6739895, DOI: 10.1097/xce.0000000000000151.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseDiabetes mellitusMedical Expenditure Panel SurveyCardiovascular diseaseMajor adverse cardiac eventsAggressive therapeutic managementAdverse cardiac eventsLower healthcare expendituresCardiac eventsSecondary preventionTherapeutic managementHealthcare costsEconomic burdenProper lifestyleHealthcare expendituresHousehold ComponentMellitusPanel SurveyDiseasePriority conditionsResource utilizationCliniciansDiagnosisIndividualsPrevention
2017
Association Between Modifiable Risk Factors and Pharmaceutical Expenditures Among Adults With Atherosclerotic Cardiovascular Disease in the United States: 2012–2013 Medical Expenditures Panel Survey
Salami JA, Valero‐Elizondo J, Ogunmoroti O, Spatz ES, Rana JS, Virani SS, Blankstein R, Younus A, Arrieta A, Blaha MJ, Veledar E, Nasir K. Association Between Modifiable Risk Factors and Pharmaceutical Expenditures Among Adults With Atherosclerotic Cardiovascular Disease in the United States: 2012–2013 Medical Expenditures Panel Survey. Journal Of The American Heart Association 2017, 6: e004996. PMID: 28600400, PMCID: PMC5669151, DOI: 10.1161/jaha.116.004996.Peer-Reviewed Original ResearchConceptsModifiable risk factorsAtherosclerotic cardiovascular diseaseCardiovascular diseaseRisk factorsPharmaceutical expenditureMedication-related expendituresSignificant marginal increaseSurvey's complex designInadequate physical activityMedical Expenditure Panel SurveyMedical Expenditure PanelHigher healthcare spendingASCVD patientsDiabetes mellitusMost deathsPhysical activityTotal pharmaceutical expenditureAdjusted relationshipMedicationsDiseaseHealthcare spendingMellitusPatientsAssociationAdultsYoung Women With Acute Myocardial Infarction
Dreyer RP, Sciria C, Spatz ES, Safdar B, D'Onofrio G, Krumholz HM. Young Women With Acute Myocardial Infarction. Circulation Cardiovascular Quality And Outcomes 2017, 10: e003480. PMID: 28228455, PMCID: PMC5502480, DOI: 10.1161/circoutcomes.116.003480.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionYoung womenMyocardial infarctionManagement of AMIPost-AMI periodContinuum of careCoronary diseaseAged menHigh riskWorse recoveryWomenInfarctionHighlight gapsRecent studiesDifferent mechanismsMorbidityHospitalMortalityEpidemiologyPublic awarenessDiseaseDiagnosisCareFavorable cardiovascular risk factor profile is associated with lower healthcare expenditure and resource utilization among adults with diabetes mellitus free of established cardiovascular disease: 2012 Medical Expenditure Panel Survey (MEPS)
Feldman DI, Valero-Elizondo J, Salami JA, Rana JS, Ogunmoroti O, Osondu CU, Spatz ES, Virani SS, Blankstein R, Blaha MJ, Veledar E, Nasir K. Favorable cardiovascular risk factor profile is associated with lower healthcare expenditure and resource utilization among adults with diabetes mellitus free of established cardiovascular disease: 2012 Medical Expenditure Panel Survey (MEPS). Atherosclerosis 2017, 258: 79-83. PMID: 28214425, DOI: 10.1016/j.atherosclerosis.2017.02.004.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedCardiovascular DiseasesCost SavingsDiabetes ComplicationsDiabetes MellitusFemaleHealth Care CostsHealth Care SurveysHealth ExpendituresHealth ResourcesHumansLogistic ModelsMaleMiddle AgedModels, EconomicOdds RatioProcess Assessment, Health CareRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsFavorable cardiovascular risk factor profileCardiovascular risk factor profileRisk factor profileDiabetes mellitusMedical Expenditure Panel SurveyLower healthcare expendituresCardiovascular diseaseCRF profileDM statusHealthcare expendituresFactor profileCVD-free individualsMean annual expenditureLifestyle modificationMean ageIndividualized prescriptionTwo-part econometric modelEconomic burdenTherapeutic treatmentMellitusDiseaseCost dataAnnual expenditureIndividualsResource utilization
2015
COMPARATIVE EFFECTIVENESS OF CARDIAC RESYNCHRONIZATION THERAPY WITH DEFIBRILLATOR VERSUS DEFIBRILLATOR ALONE IN HEART FAILURE PATIENTS WITH MODERATE TO SEVERE CHRONIC KIDNEY DISEASE
Friedman D, Singh J, Curtis J, Tang W, Bao H, Spatz E, Hernandez A, Patel U, Al-Khatib S. COMPARATIVE EFFECTIVENESS OF CARDIAC RESYNCHRONIZATION THERAPY WITH DEFIBRILLATOR VERSUS DEFIBRILLATOR ALONE IN HEART FAILURE PATIENTS WITH MODERATE TO SEVERE CHRONIC KIDNEY DISEASE. Journal Of The American College Of Cardiology 2015, 65: a452. DOI: 10.1016/s0735-1097(15)60452-1.Peer-Reviewed Original Research